Skip to content

Post-infectious IBS

TL;DR — Post-infectious IBS (PI-IBS) is the only route into IBS with a datable start, a measured incidence, a validated risk score and an eight-year prognosis, which makes it the field's best natural experiment. Pooled prevalence after acute gastroenteritis is 14.5% across 47 studies and 28,170 subjects, with odds of IBS 4.3-fold higher than in unexposed controls (Porcari 2024, PMID 39013599); an earlier Mayo synthesis put 12-month prevalence at 10.1% (95% CI 7.2–14.1) and >12-month prevalence at 14.5% (7.7–25.5), with RR 4.2 (3.1–5.7) within 12 months falling to 2.3 (1.8–3.0) beyond (Klem 2017, PMID 28069350). Pathogen class matters: parasites 30.1% (only two studies), bacteria 18.3%, viruses 10.7%, with Campylobacter at 20.7% and both Proteobacteria and SARS-CoV-2 giving the highest odds (OR 5.4 each) (Porcari 2024, PMID 39013599). The Walkerton, Ontario E. coli O157:H7/Campylobacter water outbreak of May 2000 supplies the definitive prognosis: IBS prevalence among the exposed fell from 28.3% at 2–3 years to 15.4% at 8 years but remained elevated versus controls (OR 3.12, 1.99–5.04) (Marshall 2010, PMID 20427395). Risk is concentrated in women, younger people, those with pre-existing anxiety or depression, and those with a severe or prolonged acute illness — a nine-variable risk score discriminates at AUC 0.70, separating groups with 10%, 35% and 60% PI-IBS rates (Thabane 2009, PMID 19568228). No intervention has been shown to prevent PI-IBS, and the mechanism connecting a resolved infection to years of symptoms remains unestablished.

Incidence and relative risk

Source Scope Prevalence of PI-IBS Odds/risk vs unexposed
Porcari 2024, PMID 39013599 47 studies, 28,170 subjects, ≥3 months follow-up 14.5% OR 4.3
Klem 2017, PMID 28069350 45 studies, 21,421 individuals with enteritis 10.1% (7.2–14.1) at 12 months; 14.5% (7.7–25.5) beyond 12 months RR 4.2 (3.1–5.7) ≤12 months; 2.3 (1.8–3.0) >12 months
Thabane 2007, PMID 17661757 18 of 26 studies Pooled incidence 10% Pooled OR 5.86 (3.60–9.54) at study end; 7.58 at 3 months, 5.18 at 6, 6.37 at 12, 3.85 at 24–36 months
Svendsen 2019, PMID 31112663 34 articles, by pathogen See pathogen table Bacterial AGE overall OR 5.8 (4.0–8.3); any pathogen OR 4.9 (3.9–6.1)
Schwille-Kiuntke 2015, PMID 25871571 6 studies, travellers' diarrhoea 5.4% in exposed vs 1.4% in healthy Pooled RR 3.35 (2.22–5.05), I²=5%

Note the internal consistency across independent syntheses spanning 2007–2024: roughly a 10–15% absolute risk and a 4–6-fold relative risk. This is one of the most stable quantitative findings in the whole IBS literature.

Does the pathogen matter?

Pathogen / class Pooled PI-IBS prevalence Odds ratio Source
Parasites/protozoa 30.1% (two studies only) / 41.9% — Porcari 2024, PMID 39013599; Klem 2017, PMID 28069350
Bacteria (overall) 18.3% / 13.8% OR 5.8 (4.0–8.3) Porcari 2024, PMID 39013599; Klem 2017, PMID 28069350; Svendsen 2019, PMID 31112663
Viruses (overall) 10.7% — Porcari 2024, PMID 39013599
Campylobacter spp. 20.7% (Porcari) / 12% (10–15%) (Svendsen) — PMID 39013599; PMID 31112663
Salmonella spp. 12% (9–15%) OR 5.5 (2.3–12.8) Svendsen 2019, PMID 31112663
Shigella spp. 11% (8–15%) OR 13.8 (4.2–45.4) Svendsen 2019, PMID 31112663
Clostridioides difficile 14% (4–29%) — Svendsen 2019, PMID 31112663
E. coli spp. 12% (5–20%) — Svendsen 2019, PMID 31112663
Proteobacteria — OR 5.4 Porcari 2024, PMID 39013599
SARS-CoV-2 — OR 5.4 Porcari 2024, PMID 39013599
Norovirus (single outbreak, San Felice del Benaco 2009) 13% (40 new Rome III IBS cases) OR 11.40 (3.44–37.82) Zanini 2012, PMID 22525306
Giardia (Bergen outbreak, 6-year follow-up) 39.4% Rome III IBS in exposed Adjusted RR 3.4 (2.9–3.9) Hanevik 2014, PMID 25115874

Two syntheses disagree about whether pathogen identity matters. Svendsen concludes "current literature show similar risks for bacterial pathogens" and that evidence is "insufficient to identify pathogen-specific risk factors" (PMID 31112663); Porcari finds parasites > bacteria > viruses and singles out Proteobacteria and SARS-CoV-2 (PMID 39013599). The disagreement is partly one of vintage (2019 vs 2024, with COVID-era data only in the later review) and partly of pooling scheme; the parasite estimate rests on two studies and should not be treated as established.

Walkerton: the definitive cohort

In May 2000 the municipal water supply of Walkerton, Ontario was contaminated with E. coli O157:H7 and Campylobacter jejuni. The Walkerton Health Study followed residents for eight years.

Time point Finding
2 years (n=2,069 eligible) Rome I IBS in 10.1% of 701 controls, 27.5% of 904 with self-reported gastroenteritis, 36.2% of 464 with clinically suspected gastroenteritis (all p<0.001). Independent risk factors: younger age, female sex, bloody stools, abdominal cramps, weight loss, prolonged diarrhoea. PI-IBS was more often diarrhoea-predominant than sporadic IBS (Marshall 2006, PMID 16890598)
8 years (n=1,166 eligible from 2,451 returners) IBS prevalence among 742 exposed fell from 28.3% at 2–3 years to 15.4% at 8 years, still elevated vs controls (OR 3.12, 1.99–5.04). Independent risk factors at 8 years: female sex, younger age, prior anxiety/depression, fever or weight loss during the acute illness. IBS subtypes were not stable over time (Marshall 2010, PMID 20427395)
Children (n=467, aged <16 at outbreak) Cumulative IBS incidence 10.5% in exposed vs 2.5% in controls (OR 4.6, 1.6–13.3). Risk factors mirrored adults: female sex, diarrhoea >7 days, weight loss >10 lb, antibiotic use; female sex and time-to-assessment remained independent after adjustment (Thabane 2010, PMID 20179687)
Dyspepsia Uninvestigated dyspepsia was also elevated 8 years after the outbreak (Ford 2010, PMID 20117111) — see overlap-with-functional-dyspepsia

Walkerton establishes three things no other design can: (1) symptoms persist for at least eight years after a single, dated, resolved bacterial exposure; (2) they decline but do not return to baseline; (3) the same outbreak produces both PI-IBS and post-infectious dyspepsia, which argues for a shared post-infectious diathesis rather than a bowel-specific injury.

Who develops it

Risk factors replicate across the meta-analyses and the Walkerton cohort:

Factor Effect Source
Female sex OR 2.2 (1.6–3.1) Klem 2017, PMID 28069350
Antibiotic exposure during enteritis OR 1.7 (1.2–2.4) Klem 2017, PMID 28069350
Anxiety OR 2.0 (1.3–2.9) Klem 2017, PMID 28069350
Depression OR 1.5 (1.2–1.9) Klem 2017, PMID 28069350
Somatisation OR 4.1 (2.7–6.0) Klem 2017, PMID 28069350
Neuroticism OR 3.3 (1.6–6.5) Klem 2017, PMID 28069350
Clinical severity of enteritis Significant Klem 2017, PMID 28069350; Marshall 2006, PMID 16890598
Younger age, prolonged fever Significant Thabane 2007, PMID 17661757

The Walkerton risk score. Nine variables — sex, age <60, longer duration of diarrhoea, increased stool frequency, abdominal cramping, bloody stools, weight loss, fever, and psychological disorder (anxiety/depression) — derived and split-sample-validated in 1,368 exposed patients. Area under the ROC 0.70 in both sets. PI-IBS rates in the low/intermediate/high strata were 10%/35%/60% (derivation) and 17%/36%/62% (validation) (Thabane 2009, PMID 19568228). Targeted PubMed and registry searches on 2026-09-02 retrieved no other validated pre-symptomatic IBS risk tool and no preventive trial using this score for enrichment.

The psychological risk factors, and what they do and do not mean

Anxiety, depression, somatisation and neuroticism measured before or during the acute infection all predict PI-IBS (Klem 2017, PMID 28069350; Marshall 2010, PMID 20427395). This is often read as evidence that PI-IBS is psychologically mediated. Two constraints on that reading, both from this knowledge base:

  1. The relationship is bidirectional in general population cohorts — having a functional GI disorder also predicts later anxiety and depression (Koloski 2012, PMID 22234979) — so pre-infection psychological state is a marker in a two-way system, not necessarily an upstream cause.
  2. Genetic correlation between IBS and anxiety/neuroticism/depression exceeds 0.5, and the analyses argued this reflects "shared pathogenic pathways rather than, for example, anxiety causing abdominal symptoms" (Eijsbouts 2021, PMID 34741163).

See brain-gut-axis-and-visceral-hypersensitivity.

Genetic susceptibility

The Walkerton cohort was also used to test whether host genotype determines who develops PI-IBS. Seventy-nine functional variants in genes involved in serotonergic pathways, intestinal epithelial barrier function and innate immunity were screened in 228 exposed residents who developed PI-IBS at 2–3 years versus 581 exposed residents who did not. Four variants were associated, though not after correction for the number of SNPs tested: two in TLR9 (rs352139, P=.0059; rs5743836, P=.0250), one in CDH1, encoding a tight-junction protein (rs16260, P=.0352), and one in IL6 (rs1800795, P=.0420). Denser mapping added a novel IL6 association (rs2069861, P=.0069). All three loci persisted as independent risk factors after controlling for the previously identified clinical predictors (Villani 2010, PMID 20044998).

The direction of that finding is what matters: the implicated genes govern epithelial barrier function and the innate immune response to enteric bacteria — not central pain processing. That sits alongside the later IBS GWAS, which implicated predominantly nervous-system genes (Eijsbouts 2021, PMID 34741163), and suggests that post-infectious and sporadic IBS may not share a single genetic architecture. A targeted PubMed search on 2026-09-02 retrieved no direct comparative genetic study of PI-IBS versus sporadic IBS.

Mucosal findings, and the trial that failed to exploit them

Post-infectious IBS is associated with increased serotonin-containing enterochromaffin cells and lymphocytes in rectal biopsies. That observation generated the field's most direct anti-inflammatory experiment: 29 patients with post-infectious IBS randomised to three weeks of oral prednisolone 30 mg/day or placebo, with rectal biopsies before and after (Dunlop 2003, PMID 12848628).

Outcome Prednisolone Placebo Verdict
Enterochromaffin cell count change −0.8% ± 9.2% +7.9% ± 7.9% No difference (p=0.5)
Lamina propria T-lymphocyte count change −22.0% ± 5.6% (p=0.003) −11.5% ± 8.6% (p=0.1) Steroid reduced lymphocytes
Abdominal pain, diarrhoea, frequency, urgency — — No treatment-related improvement

Baseline enterochromaffin cell counts were elevated and correlated with lamina propria T-lymphocyte counts (r=0.460, p=0.014). The trial therefore demonstrated that a steroid can suppress the mucosal immune infiltrate in PI-IBS and that doing so does not relieve symptoms. The authors' conclusion — "other approaches to this persistent condition are indicated" — has not been superseded by a positive anti-inflammatory trial in the subsequent two decades (searched 2026-09-02).

The anti-CdtB / anti-vinculin biomarker hypothesis

The most developed post-infectious mechanism with a candidate diagnostic test. Cytolethal distending toxin B (CdtB) is produced by bacteria that cause acute gastroenteritis; in a post-infectious animal model, host antibodies to CdtB cross-react with vinculin in the host gut, producing an IBS-like phenotype. Circulating antibodies to both were therefore proposed as biomarkers for IBS-D.

Study Design Result
Pimentel 2015, PMID 25970536 2,375 Rome-defined IBS-D subjects from the TARGET 3 trial versus 142 IBD, 121 coeliac disease and 43 healthy controls; plasma ELISA Both antibodies significantly higher in IBS-D than in all comparators (p<0.001). AUC for IBS-D versus IBD: 0.81 anti-CdtB, 0.62 anti-vinculin. At optimised cut-offs, anti-CdtB gave specificity 91.6%, sensitivity 43.7%, likelihood ratio 5.2; anti-vinculin gave specificity 83.8%, sensitivity 32.6%, likelihood ratio 2.0. Both were less specific in distinguishing IBS from coeliac disease
Rezaie 2017, PMID 28451914 Across IBS subtypes Subtype assessment
Morales 2019, PMID 31152332 Second-generation assay Reformulated testing
Talley 2019, PMID 31356481 Community and healthcare populations, functional dyspepsia and IBS External assessment outside the developing group
Vasapolli 2021, PMID 34390492 Microbiota profiles alongside antibody status in functional GI disorders External assessment
Barros 2024, PMID 39627697 IBS diagnosis within inflammatory bowel disease Applied to a specific differential
Schmulson 2016, PMID 27681080 Clinical experience in Mexico Real-world use

Read carefully, the original validation reports a rule-in test with sensitivity below 45%: a positive result raises the probability of IBS-D meaningfully (LR 5.2 for anti-CdtB), a negative result excludes almost nothing, and the assay performs worst against the differential (coeliac disease) that matters most in practice. It is also worth noting that the developing institution holds licensing agreements with the companies commercialising related products, as the paper's own conflict-of-interest statement records. No guideline in guidelines recommends the test, and the diagnostic-accuracy meta-analysis that examined eleven candidate biomarkers concluded none performed better than symptom-based criteria (Sood 2015, PMID 26076071).

Prognosis

  • Prevalence declines slowly: 28.3% → 15.4% over 5–6 years of follow-up in Walkerton (Marshall 2010, PMID 20427395); Rome III IBS after Giardia fell by 6.7% (RR 0.85, 0.77–0.93) between year 3 and year 6 (Hanevik 2014, PMID 25115874).
  • IBS persisted in 39.8% of subjects at >5 years follow-up in the 2024 pooled analysis (Porcari 2024, PMID 39013599).
  • Relative risk decays but does not vanish: RR 4.2 within 12 months, 2.3 beyond (Klem 2017, PMID 28069350).
  • Subtype is unstable over time even within this well-defined cohort (Marshall 2010, PMID 20427395), which limits the value of subtype-directed treatment in PI-IBS.

Mechanism: what is proposed and what is shown

The 2026 pathophysiology review lists gastrointestinal infection first among peripheral mechanisms and connects it to microbiome change, permeability, low-grade mucosal immune activation and serotonin signalling (Nasser 2026, PMID 42462748). Giardia sequelae extend beyond the gut to chronic fatigue, arthritis and fibromyalgia, "research has yet to fully elucidate underlying mechanisms" (Miko 2025, PMID 41570191). What is not established: which of the candidate mechanisms is necessary, why only ~1 in 7 exposed people develops PI-IBS, and why the same exposure produces bowel symptoms in some and dyspepsia in others (Ford 2010, PMID 20117111).

Open questions

  • Can PI-IBS be prevented? A validated risk score exists (Thabane 2009, PMID 19568228); targeted PubMed and registry searches on 2026-09-02 retrieved no preventive intervention trial in high-risk acute gastroenteritis and no trial using the score for enrichment.
  • Does antibiotic exposure during enteritis cause PI-IBS or mark severity? The OR is 1.7 (1.2–2.4) (Klem 2017, PMID 28069350) and observational.
  • Does pathogen identity matter? Two meta-analyses disagree (Svendsen 2019, PMID 31112663 vs Porcari 2024, PMID 39013599).
  • Is post-COVID IBS the same entity? SARS-CoV-2 carries OR 5.4 for PI-IBS (Porcari 2024, PMID 39013599) but the mechanism — direct enteric infection, systemic inflammation, or pandemic-era stress — has not been separated.
  • Why do parasitic infections carry the highest reported risk (30.1%–41.9%) on the thinnest evidence base (Porcari 2024, PMID 39013599; Klem 2017, PMID 28069350)?
  • Does PI-IBS respond differently to treatment than sporadic IBS? No treatment trial has stratified by post-infectious onset.
  • What explains the parallel emergence of post-infectious dyspepsia in the same cohort (Ford 2010, PMID 20117111)?
  • Do TLR9, CDH1 and IL6 variants replicate outside Walkerton, and do they distinguish post-infectious from sporadic IBS (Villani 2010, PMID 20044998)? The associations did not survive multiple-testing correction in the original study.
  • Why did suppressing the mucosal lymphocyte infiltrate not relieve symptoms (Dunlop 2003, PMID 12848628)? Either the infiltrate is not causal, or three weeks of prednisolone is the wrong intervention; a targeted PubMed search on 2026-09-02 retrieved no later PI-IBS anti-inflammatory trial distinguishing these explanations.
  • Is the anti-CdtB / anti-vinculin biomarker clinically useful given sensitivity of 43.7% and 32.6% and poorer performance against coeliac disease (Pimentel 2015, PMID 25970536)? No guideline recommends it.

References

  1. Porcari S, et al. Prevalence of irritable bowel syndrome and functional dyspepsia after acute gastroenteritis: systematic review and meta-analysis. Gut. 2024;73(9):1431-1440. PMID 39013599
  2. Klem F, et al. Prevalence, Risk Factors, and Outcomes of Irritable Bowel Syndrome After Infectious Enteritis: A Systematic Review and Meta-analysis. Gastroenterology. 2017;152(5):1042-1054.e1. PMID 28069350
  3. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26(4):535-44. PMID 17661757
  4. Svendsen AT, Bytzer P, Engsbro AL. Systematic review with meta-analyses: does the pathogen matter in post-infectious irritable bowel syndrome? Scand J Gastroenterol. 2019;54(5):546-562. PMID 31112663
  5. Schwille-Kiuntke J, Mazurak N, Enck P. Systematic review with meta-analysis: post-infectious irritable bowel syndrome after travellers' diarrhoea. Aliment Pharmacol Ther. 2015;41(11):1029-37. PMID 25871571
  6. Marshall JK, et al. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology. 2006;131(2):445-50. PMID 16890598
  7. Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM; Walkerton Health Study Investigators. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 2010;59(5):605-11. PMID 20427395
  8. Thabane M, et al. An outbreak of acute bacterial gastroenteritis is associated with an increased incidence of irritable bowel syndrome in children. Am J Gastroenterol. 2010;105(4):933-9. PMID 20179687
  9. Thabane M, Simunovic M, Akhtar-Danesh N, Marshall JK. Development and validation of a risk score for post-infectious irritable bowel syndrome. Am J Gastroenterol. 2009;104(9):2267-74. PMID 19568228
  10. Ford AC, et al. Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. Gastroenterology. 2010;138(5):1727-36. PMID 20117111
  11. Zanini B, et al. Incidence of post-infectious irritable bowel syndrome and functional intestinal disorders following a water-borne viral gastroenteritis outbreak. Am J Gastroenterol. 2012;107(6):891-9. PMID 22525306
  12. Hanevik K, Wensaas KA, Rortveit G, Eide GE, Mørch K, Langeland N. Irritable bowel syndrome and chronic fatigue 6 years after giardia infection: a controlled prospective cohort study. Clin Infect Dis. 2014;59(10):1394-400. PMID 25115874
  13. Miko S, Kache PA, Imada E, Freeland AL, Haston JC. Postinfectious Syndromes and Long-Term Sequelae after Giardia Infections. Emerg Infect Dis. 2025;31(14):45-52. PMID 41570191
  14. Koloski NA, Jones M, Kalantar J, Weltman M, Zaguirre J, Talley NJ. The brain-gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut. 2012;61(9):1284-90. PMID 22234979
  15. Eijsbouts C, et al. Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. Nat Genet. 2021;53(11):1543-1552. PMID 34741163
  16. Villani AC, et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology. 2010;138(4):1502-13. PMID 20044998
  17. Dunlop SP, Jenkins D, Neal KR, Naesdal J, Borgaonker M, Collins SM, Spiller RC. Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2003;18(1):77-84. PMID 12848628
  18. Pimentel M, et al. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PLoS One. 2015;10(5):e0126438. PMID 25970536
  19. Rezaie A, et al. Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome. Dig Dis Sci. 2017;62(6):1480-1485. PMID 28451914
  20. Morales W, et al. Second-Generation Biomarker Testing for Irritable Bowel Syndrome Using Plasma Anti-CdtB and Anti-Vinculin Levels. Dig Dis Sci. 2019;64(11):3115-3121. PMID 31152332
  21. Talley NJ, et al. Circulating Anti-cytolethal Distending Toxin B and Anti-vinculin Antibodies as Biomarkers in Community and Healthcare Populations With Functional Dyspepsia and Irritable Bowel Syndrome. Clin Transl Gastroenterol. 2019;10(7):e00064. PMID 31356481
  22. Vasapolli R, et al. Gut microbiota profiles and the role of anti-CdtB and anti-vinculin antibodies in patients with functional gastrointestinal disorders (FGID). Eur J Clin Invest. 2021;51(12):e13666. PMID 34390492
  23. Barros LL, et al. Anti-CdtB and anti-vinculin antibodies to diagnose irritable bowel syndrome in inflammatory bowel disease patients. BMC Gastroenterol. 2024;24:448. PMID 39627697
  24. Schmulson M, et al. Clinical experience with the use of anti-CdtB and anti-vinculin antibodies in patients with diarrhea in Mexico. Rev Gastroenterol Mex. 2016;81(4):236-239. PMID 27681080
  25. Sood R, Gracie DJ, Law GR, Ford AC. Systematic review with meta-analysis: the accuracy of diagnosing irritable bowel syndrome with symptoms, biomarkers and/or psychological markers. Aliment Pharmacol Ther. 2015;42(5):491-503. PMID 26076071
  26. Nasser Y, Shin A, Ford AC, Camilleri M, Black CJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2026 Jul 16 (online ahead of print). PMID 42462748